

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 84-87 without prejudice or disclaimer.

Please amend pending claims 2, 5, 9, 14 and 81 as noted below.

1. (Cancelled)
2. (Currently amended) An isolated HLA DRB1*15-binding peptide consisting of the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition or substitution, and 0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition, or substitution or deletion.
- 3-4. (Cancelled)
5. (Currently Amended) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide further comprises an endosomal targeting signal.
6. (Cancelled)
7. (Previously presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide is non-hydrolyzable.
8. (Cancelled)
9. (Currently amended) A composition comprising an isolated MAGE-A1 HLA class I-binding peptide and an isolated MAGE-A1 HLA DRB1*15-binding peptide, wherein the isolated HLA class II-binding peptide consists of

the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition; or substitution-or deletion, and

0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof consisting of one amino acid addition; or substitution-or deletion, and

wherein the HLA class I-binding peptide and the HLA class II-binding peptide are separate isolated peptides.

10-13 (Cancelled)

14. (Currently Amended) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide further comprises an endosomal targeting signal.

15.-75. (Cancelled)

76. (Previously Presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition or substitution.

77. (Previously Presented) The isolated HLA DRB1*15-binding peptide of claim 2 wherein the isolated peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

78. (Previously Presented) The isolated HLA DRB1*15-binding peptide of claim 5 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain Ii or LAMP-1.

79. (Previously Presented) The isolated HLA DRB1*15-binding peptide of claim 7 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -

psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

80. (Cancelled)
81. (Currently Amended) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7, or a functional variant thereof consisting of one amino acid addition, or substitution-~~or deletion~~.
82. (Previously Presented) The composition of claim 9 wherein the isolated MAGE-A1 HLA DRB1*15-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.
83. (Previously Presented) The composition of claim 14 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain II or LAMP-1.
- 84.-87. (Cancelled)